4D Molecular TherapeuticsÂ Inc (FDMT) Financials

$13.17

$-0.32 (-2.37%)

As on 11-Sep-2026 16:00EDT

Market cap

$827 Mln

Revenue (TTM)

$92 Mln

P/E Ratio

--

P/B Ratio

2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	92.01	85.21	0.04	20.72	3.13	18.04
Cost of Revenue	53.36	7.63	141.30	97.10	3.88	3.02
Gross Profit	38.65	77.58	-141.26	-76.37	3.13	18.04
Operating Expenses	235.76	237.13	46.58	36.49	113.16	89.37
Operating Profit (EBIT)	-197.12	-159.55	-187.84	-112.87	-110.03	-71.33
Other Income	--	--	--	--	2.54	0.02
Profit before Tax	-179.18	-140.11	-160.87	-100.84	-107.49	-71.32
Provision for Tax	--	--	--	5.58	-6.42	-3.02
Profit after Tax (Net Income)	-179.18	-140.11	-160.87	-100.84	-101.08	-68.30
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-107.49	-71.32

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	407.66	505.66	510.61	307.83	231.34	319.11
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	37.28	17.06	20.63	13.11	14.78	18.04
Current Liabilities	47.67	43.99	29.15	18.95	15.73	16.34
Total Liabilities	540.29	566.71	560.38	339.89	261.85	353.49

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	109.66	153.58	125.45	43.30	41.34	97.21
Current Assets	382.96	413.13	434.93	296.59	220.51	256.28
Total Assets	540.29	566.71	560.38	339.89	261.85	353.49
Total Debt*	39.22	21.41	24.61	14.67	16.12	16.45
Net Current Assets	335.28	369.15	405.78	277.64	204.78	239.94

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-109.08	-134.59	-75.79	-86.69	-69.13
Cash Flow from Investing Activities	--	-92.97	-302.44	115.72	-17.05	-172.68
Cash from Financing Activities	--	112.96	337.25	156.83	3.09	118.09
Net Cash Inflow / Outflow	--	--	--	--	-100.65	-123.73

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-2.73	-2.42	-2.98	-2.58	-3.11	-2.53
Cash EPS ($)	--	-2.29	-2.86	-2.43	-2.99	-2.42
Adjusted Book Value ($)	--	8.73	9.47	7.87	7.12	11.81
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.88	-2.49	-1.94	-2.67	-2.56
Free Cash Flow per Share ($)	--	-1.88	-2.57	-2.01	-3.02	-2.90

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-26.38	-37.51	-35.38	-34.67	-23.08
ROE (%)	-39.24	-27.57	-39.31	-37.40	-36.73	-23.74
ROA (%)	-34.17	-24.86	-35.74	-33.52	-32.85	-21.28
EBIT Margin (%)	-208.95	-164.43	-434,778.38	-486.59	-3,516.52	-395.46
Net Margin (%)	-194.74	-164.43	-434,778.38	-486.59	-1,783.59	-378.29
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	278,712.12	2,301.95	-1.00	5.62	-0.83	0.33
EBIT Growth (%)	1.98	12.90	-59.53	8.36	-54.25	-25.89
Net Profit Growth (%)	8.65	12.90	-59.53	0.24	-47.99	-20.47
EPS Growth (%)	23.15	0.19	-0.16	0.17	-0.23	-0.19
Book Value Growth (%)	-22.92	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-3.10	-1.87	-7.86	-7.14	-8.68
Price / Book Value	1.99	0.86	0.59	2.58	3.12	1.86
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-3.55	-0.40	0.65	-5.37	-4.94	-5.29
Close Price ($)	13.30	7.50	5.57	20.26	22.21	21.94
High Price ($)	14.00	12.34	36.25	24.10	26.49	55.11
Low Price ($)	3.68	2.24	5.22	9.44	5.32	18.57
Market Cap ($ Cr)	827.01	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	0.05	0.04	0.05	0.05	0.07	0.05
Short term debt to equity ratio	0.01	0.01	0.01	0.01	0.01	0.00
Current Ratio	8.03	9.39	14.92	15.65	14.02	15.69
Quick Ratio	8.03	--	--	--	14.39	16.21
Interest Coverage	--	--	--	--	-17.14	-23.50

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	5.01	--	--	--	22.37	0.26
Asset Turnover	0.18	0.15	0.00	0.07	0.01	0.06
Receivable days	--	--	--	12.34	43.60	15.52
Inventory Days	--	--	--	-21.77	-672.65	-1,028.38
Payable days	--	372.32	10.21	12.86	380.59	396.15
Cash Conversion Cycle	--	--	--	-22.29	-1,009.65	-1,409.01

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.